ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-22-552-3840
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees39
OptionableNot Optionable
Obseva (NASDAQ:OBSV) Frequently Asked Questions
What is Obseva's stock symbol?
Obseva trades on the NASDAQ under the ticker symbol "OBSV."
How were Obseva's earnings last quarter?
Obseva SA (NASDAQ:OBSV) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.04. View Obseva's Earnings History.
When is Obseva's next earnings date?
What price target have analysts set for OBSV?
6 equities research analysts have issued twelve-month price objectives for Obseva's shares. Their forecasts range from $24.00 to $44.00. On average, they anticipate Obseva's share price to reach $31.1667 in the next year. This suggests a possible upside of 131.7% from the stock's current price. View Analyst Price Targets for Obseva.
What is the consensus analysts' recommendation for Obseva?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.
What are Wall Street analysts saying about Obseva stock?
Here are some recent quotes from research analysts about Obseva stock:
- 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (1/16/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.83B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban. The current total valuation of $2.2B translates to $44.00 per share, assuming roughly 49M fully-diluted shares outstanding as of end-2019. The fully-diluted shares projected in 12 months includes the exercise of all remaining outstanding options, as well as an equity financing involving the sale of roughly 2M shares in 1H19." (12/10/2018)
Has Obseva been receiving favorable news coverage?
Headlines about OBSV stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Obseva earned a news sentiment score of 3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are some of Obseva's key competitors?
Some companies that are related to Obseva include Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Innoviva (INVA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR), Insmed (INSM), Madrigal Pharmaceuticals (MDGL), Myokardia (MYOK), Zogenix (ZGNX), Allakos (ALLK), Portola Pharmaceuticals (PTLA), PTC Therapeutics (PTCT), Corcept Therapeutics (CORT) and Mallinckrodt (MNK).
Who are Obseva's key executives?
Obseva's management team includes the folowing people:
- Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
- Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
- Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
- Mr. Mario Vincent Corso, Sr. Director of Investor Relations
- Dr. Elke Bestel, Chief Medical Officer & Head of Pharmacovigilance (Age 53)
When did Obseva IPO?
(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.
How do I buy shares of Obseva?
Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obseva's stock price today?
One share of OBSV stock can currently be purchased for approximately $13.45.
How big of a company is Obseva?
Obseva has a market capitalization of $500.63 million. The company earns $-66,920,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Obseva employs 39 workers across the globe.
What is Obseva's official website?
How can I contact Obseva?
Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]
MarketBeat Community Rating for Obseva (NASDAQ OBSV)
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
